Cancer Stem Cells Market By Cancer Forms (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Others), By Application (Trageted Cancerous Stem Cells, Stem Cell-based cancer Therapy): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global cancer stem cells market is envisioned to garner $2,711.8 million by 2031, growing from $1,055.2 million in 2021 at a CAGR of 10.0% from 2022 to 2031.
Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.
The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.
Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.
The key players profiled in this report include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.
Key Market Segments
By Cancer Forms
Breast
Blood
Lung
Brain
Colorectal
Pancreatic
Bladder
Liver
Others
By Application
Trageted Cancerous Stem Cells
Stem Cell-based cancer Therapy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
Thermo Fisher Scientific Inc.
AbbVie Inc.
Miltenyi Biotec
STEMCELL Technologies Inc.
Merck KGaA
Stemline Therapeutics, Inc.
MacroGenics, Inc.
Bionomics
FUJIFILM Irvine Scientific.
Lineage Cell Therapeutics, Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook